세계의 팍스로비드 API 시장 규모 조사 및 예측 : 유형별(순도 99% 이상, 순도 99.5% 이상), 용도별(COVID-19 경구약, 연구용 시약, 기타), 지역별 분석(2023-2030년)

Global Paxlovid API Market is valued at approximately USD XXX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Paxlovid is a medicine that combines two antiviral drugs. It is authorized for the treatment of mild to moderate COVID-19 illnesses. The increasing demand for Paxlovid API in the pharmaceutical industry is the key factor responsible for market growth over the forecast period of 2023-2030.

The primary key factor anticipated to accelerate the growth of the Paxlovid API Market is the increasing demand in the pharmaceutical industry for the treatment of Covid illness. For instance- according to the World Health Organization, In Apr 2020, SARS-CoV-2 spread to over 209 countries and territories, with over 2,314,621 confirmed coronavirus cases recorded and 157,847 deaths globally. Also, increasing funding by the government for research and development for medications for COVID-19 and growing healthcare expenditure are creating a lucrative growth prospectus for the market over the forecast period. Moreover, the growing aging population and technological advancements create a positive outlook for the market. However, side effects of Paxlovid stifle market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Paxlovid API Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in terms of revenue owing to factors such as growing investments by the government in research & development in the biomedical and pharmaceuticals industry. Asia-Pacific is the fastest-growing region due to technology replacement and continuous innovations.

Major market player included in this report are:

• Pfizer Inc
• Merck & Co. Inc.
• Ridgeback Biotherapeutics LP
• Cipla Limited
• Hetero Labs Limited
• Sun Pharmaceutical Industries Ltd.
• Laurus Labs Limited
• Dr. Reddy's Laboratories Ltd.
• Mylan N.V.
• Torrent Pharmaceuticals Ltd.

Recent Developments in the Market:

• In June 2022, Pfizer has invested $120 million to produce oral treatment for COVID-19, Paxlovid, with the expansion creating more than 250 high-skilled manufacturing jobs at the company's site in Michigan.

Global Paxlovid API Market Report Scope:

• Historical Data: 2020 - 2021
• Base Year for Estimation: 2022
• Forecast period: 2023-2030
• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: Type, Application, Region
• Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
• The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Type:

• Purity ≥99%
• Purity ≥99.5%

By Application:

• COVID-19 Oral Drugs
• Research Reagents
• Other

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Paxlovid API Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2. Paxlovid API Market, by Type, 2020-2030 (USD Billion)
  • 1.2.3. Paxlovid API Market, by Application, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Paxlovid API Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Paxlovid API Market Dynamics

• 3.1. Paxlovid API Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Increasing demand in pharmaceutical industry
    • 3.1.1.2. Increasing funding by the government for research
  • 3.1.2. Market Challenges
    • 3.1.2.1. Side effects of Paxlovid
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Growing aging population
    • 3.1.3.2. Growing technological advancement in healthcare

Chapter 4. Global Paxlovid API Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Paxlovid API Market, by Type

• 5.1. Market Snapshot
• 5.2. Global Paxlovid API Market by Type, Performance - Potential Analysis
• 5.3. Global Paxlovid API Market Estimates & Forecasts by Type 2020-2030 (USD Billion)
• 5.4. Paxlovid API Market, Sub Segment Analysis
  • 5.4.1. Purity ≥99%
  • 5.4.2. Purity ≥99.5%

Chapter 6. Global Paxlovid API Market, by Application

• 6.1. Market Snapshot
• 6.2. Global Paxlovid API Market by Application, Performance - Potential Analysis
• 6.3. Global Paxlovid API Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
• 6.4. Paxlovid API Market, Sub Segment Analysis
  • 6.4.1. COVID-19 Oral Drugs
  • 6.4.2. Research Reagents
  • 6.4.3. Other

Chapter 7. Global Paxlovid API Market, by Distribution Channel

• 7.1. Market Snapshot
• 7.2. Global Paxlovid API Market by Distribution Channel, Performance - Potential Analysis

Chapter 8. Global Paxlovid API Market, Regional Analysis

• 8.1. Top Leading Countries
• 8.2. Top Emerging Countries
• 8.3. Paxlovid API Market, Regional Market Snapshot
• 8.4. North America Paxlovid API Market
  • 8.4.1. U.S. Paxlovid API Market
    • 8.4.1.1. Type breakdown estimates & forecasts, 2020-2030
    • 8.4.1.2. Application breakdown estimates & forecasts, 2020-2030
  • 8.4.2. Canada Paxlovid API Market
• 8.5. Europe Paxlovid API Market Snapshot
  • 8.5.1. U.K. Paxlovid API Market
  • 8.5.2. Germany Paxlovid API Market
  • 8.5.3. France Paxlovid API Market
  • 8.5.4. Spain Paxlovid API Market
  • 8.5.5. Italy Paxlovid API Market
  • 8.5.6. Rest of Europe Paxlovid API Market
• 8.6. Asia-Pacific Paxlovid API Market Snapshot
  • 8.6.1. China Paxlovid API Market
  • 8.6.2. India Paxlovid API Market
  • 8.6.3. Japan Paxlovid API Market
  • 8.6.4. Australia Paxlovid API Market
  • 8.6.5. South Korea Paxlovid API Market
  • 8.6.6. Rest of Asia Pacific Paxlovid API Market
• 8.7. Latin America Paxlovid API Market Snapshot
  • 8.7.1. Brazil Paxlovid API Market
  • 8.7.2. Mexico Paxlovid API Market
• 8.8. Middle East & Africa Paxlovid API Market
  • 8.8.1. Saudi Arabia Paxlovid API Market
  • 8.8.2. South Africa Paxlovid API Market
  • 8.8.3. Rest of Middle East & Africa Paxlovid API Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
  • 9.1.1. Company 1
  • 9.1.2. Company 2
  • 9.1.3. Company 3
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Pfizer Inc
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Recent Development
  • 9.3.2. Merck & Co. Inc.
  • 9.3.3. Ridgeback Biotherapeutics LP
  • 9.3.4. Cipla Limited
  • 9.3.5. Hetero Labs Limited
  • 9.3.6. Sun Pharmaceutical Industries Ltd.
  • 9.3.7. Laurus Labs Limited
  • 9.3.8. Dr. Reddy's Laboratories Ltd.
  • 9.3.9. Mylan N.V.
  • 9.3.10. Torrent Pharmaceuticals Ltd.

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes
• 10.3. Research Assumption